Clinical
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer
Summary
This phase 1-2 study investigated the safety and efficacy of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated advanced RAS-mutant non-small-cell lung cancer (NSCLC). Patients received daily oral doses ranging from 10 to 400 mg. Results indicated that 99% of patients experienced adverse events of any grade, and 54% had grade 3 or higher events, with common side effects including rash and diarrhea. Antitumor activity, assessed by objective response rate, was over 30% across the evaluated dose groups.
Critical appraisal
This phase 1-2 trial evaluates daraxonrasib for RAS-mutant NSCLC, a patient population with limited treatment options after prior therapy. Objective response rates exceeding 30% are promising for a second-line or later treatment, suggesting significant clinical activity. However, the safety profile, with 54% of patients experiencing grade 3 or higher adverse events, necessitates careful management. These findings warrant further clinical development in later-phase trials to confirm efficacy and better characterize the benefit-risk ratio, potentially leading to integration into clinical practice in the medium term (3-5 years) if data are sustained.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology